CD274 and small cell lung carcinoma: Currently, in many European Union countries, the standard first-line treatment for patients with extensive-stage SCLC (ED-SCLC) involves the use of antibodies targeting programmed death ligand 1 (PD-L1)—atezolizumab or durvalumab—in combination with chemotherapy based on platinum compounds and etoposide [5].